$81.5 Million is the total value of Asymmetry Capital Management, L.P.'s 33 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 137.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PTCT | Buy | PTC THERAPEUTICS | $9,200,000 | +29.3% | 551,558 | +55.2% | 12.49% | +51.4% |
DGX | Buy | QUEST DIAGNOSTICS | $6,265,000 | +75.0% | 63,610 | +66.4% | 8.50% | +104.8% |
JAZZ | Buy | JAZZ PHARMACEUTICALS | $6,056,000 | -1.6% | 44,976 | +6.9% | 8.22% | +15.1% |
OPTN | New | OPTINOSE INC | $5,682,000 | – | 300,618 | +100.0% | 7.71% | – |
FOLD | Buy | AMICUS THERAPEUTICS INC | $3,071,000 | -4.4% | 213,413 | +0.2% | 4.17% | +11.9% |
AERI | Buy | AERIE PHARMACEUTICALS INC | $2,410,000 | +175.7% | 40,330 | +124.4% | 3.27% | +222.6% |
HRTX | Buy | HERON THERAPEUTICS | $1,795,000 | +76.5% | 99,181 | +57.5% | 2.44% | +106.6% |
NVRO | Buy | NEVRO CORP | $1,642,000 | +53.0% | 23,785 | +101.5% | 2.23% | +79.2% |
PRGO | New | PERRIGO CO PLC | $1,580,000 | – | 18,129 | +100.0% | 2.14% | – |
TEVA | New | TEVA PHARMACEUTICALadr | $1,310,000 | – | 69,124 | +100.0% | 1.78% | – |
SGYPQ | Buy | SYNERGY PHARMACEUTICALS INC | $1,065,000 | +35.5% | 477,621 | +76.2% | 1.44% | +58.4% |
BMRN | New | BIOMARIN PHARMACEUTICAL INC | $957,000 | – | 10,733 | +100.0% | 1.30% | – |
ADMS | New | ADAMAS PHARMACEUTICALS INC | $858,000 | – | 25,311 | +100.0% | 1.16% | – |
ARRY | New | ARRAY BIOPHARMA INC | $846,000 | – | 66,095 | +100.0% | 1.15% | – |
PBYI | New | PUMA BIOTECHNOLOGYINC | $729,000 | – | 7,371 | +100.0% | 0.99% | – |
SNDX | New | SYNDAX PHARMACEUTICALS INC | $539,000 | – | 61,530 | +100.0% | 0.73% | – |
ECYT | New | ENDOCYTE | $349,000 | – | 81,484 | +100.0% | 0.47% | – |
KALA | New | KALA PHARMACEUTICALS | $250,000 | – | 13,504 | +100.0% | 0.34% | – |
PRTO | New | PROTEON THERAPEUTICS INC | $18,000 | – | 9,400 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CENTENE CORP | 21 | Q4 2021 | 10.7% |
UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
NEVRO CORP | 12 | Q3 2018 | 7.2% |
NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2022-01-19 |
13F-HR | 2021-11-04 |
13F-HR | 2021-07-28 |
13F-HR | 2021-05-11 |
13F-HR | 2021-02-11 |
13F-HR | 2020-11-12 |
13F-HR | 2020-08-06 |
13F-HR | 2020-05-13 |
13F-HR | 2020-02-12 |
13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.